Introduction {#Sec1}
============

Head and neck cancer is the sixth most common cancer worldwide \[[@CR1]\] with approximately 690,000 new cases annually worldwide, which accounts for 4.9 % of the total cancer incidence \[[@CR2]\]. Patients diagnosed with head and neck cancer face unique challenges, because the effects of the cancer and its treatment are in many cases visible and have a strong negative impact on diverse functions. Impaired speech, drooling, difficulty chewing, and altered facial appearance are just a few examples, and these changes can influence social interactions and alter patients' self-esteem \[[@CR3]\]. In addition, of the patients recently diagnosed with head and neck cancer 28--29 % is experiencing depressive symptoms \[[@CR4]\], which is 28--39 % after 6 months \[[@CR4], [@CR5]\] and 20 % at 1 year after treatment \[[@CR6]\]. Several interventions have proven effective in decreasing depressive symptoms in these patients \[[@CR7]--[@CR11]\]. We recently found that the nurse counseling and after intervention (NUCAI), a psychosocial intervention, effectively decreased depressive symptoms 1 year after treatment of head and neck cancer \[[@CR11]\]. Although this intervention is currently offered to all patients, it might not be effective in some patients. In order to gain more insight into which patients might benefit from the intervention, knowledge is needed of the variables that moderate the effect of the intervention \[[@CR12]\].

A recent systematic review \[[@CR13]\] identified 14 significant variables that moderate the outcomes of interventions in patients with cancer. For example, patients with a poor global quality of life (QoL), poor interpersonal relationships, and high emotional expressiveness appeared to benefit more than other patients. However, the review included a rather broad range of interventions, such as psychosocial, psycho-educational, and mind-body interventions aiming to increase psychosocial well-being. Less is known about which variables moderate depressive symptoms in patients with head and neck cancer. In a literature search, we found younger age \[[@CR14], [@CR15]\], female gender \[[@CR16]\], lower educational level \[[@CR17], [@CR18]\], living alone and unemployment \[[@CR19]\], higher tumor stage \[[@CR14], [@CR20]\], adjuvant chemotherapy \[[@CR16]\], smoking and daily drinking \[[@CR17]\], avoidance and helpless coping \[[@CR4], [@CR21], [@CR22]\], lower social support \[[@CR23], [@CR24]\], lower global QoL \[[@CR15], [@CR19], [@CR25], [@CR26]\], lower physical functioning \[[@CR27]\], lower emotional functioning \[[@CR28]\], lower social functioning \[[@CR27]\], higher level of pain \[[@CR29], [@CR30]\], more intrusive thoughts \[[@CR31]\], lower self-esteem \[[@CR32]\], and lower self-efficacy \[[@CR32], [@CR33]\] to influence depressive symptoms in patients with cancer. The purpose of the current study was to investigate whether these variables, which are associated with depressive symptoms in cancer patients, moderate the response to a nurse-led psychosocial intervention \[[@CR11]\] for the treatment of depressive symptoms in head and neck cancer patients.

Materials and methods {#Sec2}
=====================

This study is a secondary analysis of a randomized controlled trial (RCT) evaluating the effect of the NUCAI, a psychosocial intervention, in patients with head and neck cancer (registration number ISRCTN06768231). Newly diagnosed patients were randomly allocated to an intervention or control group. Patients in the control group received care as usual, which consists of a 10-min medical checkup by a specialist in head and neck cancer in the outpatient clinic every 2 months during the first year after cancer treatment. In addition to care as usual, patients in the intervention group received the NUCAI, which consists of six counseling sessions of 60 min during the first year after cancer treatment, given by a trained nurse. The 2-monthly sessions were combined with the medical checkup. Participants completed seven questionnaires at home, before the start of cancer treatment which is considered as baseline measurement, and at 3, 6, 9, 12, 18, and 24 months after cancer treatment. The primary endpoint was depressive symptoms 12 months after completion of cancer treatment; the other measurements were taken to gain insight into the pattern of change in depressive and health-related QoL variables.

Results showed that the NUCAI decreased depressive symptoms and improved physical functioning, emotional functioning, and pain 12 months after the completion of cancer treatment \[[@CR11]\]. More details and other, long-term findings are previously published elsewhere \[[@CR11], [@CR34]\].

Patients {#Sec3}
--------

Participants were recruited between January 2005 and September 2007 from the outpatient oral maxillofacial and the otorhinolaryngology clinics of a Dutch university hospital before the start of cancer treatment. Eligibility criteria were a primary diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx; treatment with curative intent; ability to complete questionnaires; and ability to participate in the intervention. Patients were excluded if they had a previous or concomitant malignancy and/or were being treated for depression at time of enrollment or before. Depression was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders \[[@CR35]\], as stated in the patients' medical record. Note that patients without ongoing treatment for depression were eligible for the trial. After completion of cancer treatment, participants were randomized to the intervention or control group, stratified by gender and tumor stage. Of the 328 eligible patients 63 % (*n* = 205) agreed to participate, 103 participants in the intervention group and 102 participants in the control group. At 12 months, 28 participants were lost to follow-up in the intervention group and 27 participants in the control group. Mean reasons were death (*n* = 16 in intervention group, *n* = 17 in control group) and being terminally ill (*n* = 4 in intervention group, *n* = 2 in control group). A total of 146 participants had complete data for analyses. The study was approved by the Medical Ethics Committee of the University Medical Centre Utrecht. Eligible patients received verbal and written information about the study, and all participants provided written informed consent.

Measures {#Sec4}
--------

### Sociodemographic, disease-related, and treatment-related variables {#FPar1}

Information on age (continuous), gender (male, female), education level (low (i.e., elementary and lower vocational education), middle (i.e., secondary and secondary vocational education), high (i.e., higher vocational and university education), marital status (married/living together, single), employment status (employed, not employed, retired), smoking (yes, no), and daily drinking (\<3 units alcohol a day, \>3 units alcohol a day) was collected by means of self-report questionnaires. Information about type of cancer (oral cavity/oropharynx, hypopharynx/larynx), tumor stage (I--II, III--IV), and treatment (surgery, radiotherapy, chemoradiation, combination) was obtained from medical records.

### Depressive symptoms {#FPar2}

Depressive symptoms were measured with the CES-D \[[@CR36]\]. This 20-item self-report questionnaire gives a total score ranging from 0 to 60. A high score reflects a high level of depression. The CES-D has shown good psychometric properties in Dutch patients with head and neck cancer \[[@CR4]\].

### Health-related quality of life (HRQoL) {#FPar3}

Global QoL, physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning were assessed with the EORTC QLQ-C30 version 3.0 \[[@CR37]\] and pain with the head and neck module QLQ H&N35 \[[@CR38]\]. A range of 0--100 is used and a high score reflects a high level of functioning or a high level of pain. Both are widely used and have good psychometric properties in patients with head and neck cancer \[[@CR38], [@CR39]\].

### Coping strategy {#FPar4}

Coping was assessed with the shortened Dutch version of the Coping Inventory for Stressful Situations (CISS) \[[@CR40]\]. This 21-item self-report questionnaire measures three dimensions of coping: task-oriented, emotion-oriented, and avoidance-oriented coping. Item scores range from 1 (not at all) to 5 (very often). A higher score on each dimension reflects a higher probability of using that coping strategy. The CISS demonstrated good psychometric properties in Dutch patient with internal diseases \[[@CR41]\].Chronbach's alpha in the present sample was 0.83 for the task-oriented scale, 0.83 for the emotion-oriented scale, and 0.71 for the avoidance-oriented scale.

### Social support {#FPar5}

Social support was measured with the short version of the Social Support List - Interactions (SSL 12-I) \[[@CR42]\]. This questionnaire assesses the extent of perceived received social support by means of social interactions with members of the primary social network. It consists of 12 items with possible item scores ranging from 1 (seldom or never) to 4 (very often) with a higher score reflecting more social support. The SSL 12-I has shown good psychometric properties in Dutch elderly \[[@CR42]\] and Dutch patients with rheumatoid arthritis \[[@CR43]\]. Chronbach's alpha in the present sample was 0.91.

Potential moderators {#Sec5}
--------------------

The following variables were entered in the analyses: age, gender, educational level, marital status, employment status, tumor stage, type of treatment, smoking, daily drinking, task coping, emotion coping, avoidance coping; social support, global QoL, physical functioning, emotional functioning, social functioning, and pain. These variables have been reported in the literature to be associated with depressive symptoms. We additionally included the variables assessed in the NUCAI study, namely, head and neck cancer specific tumor site, role functioning and cognitive functioning, even though there is no evidence in the literature that these variables have a moderating effect. The variables intrusive thoughts, self-esteem, and self-efficacy, which showed to be associated with depressive symptoms, could not be included in the moderator analyses because we did not collect these variables in the NUCAI study. Overall, 21 variables were selected for analysis.

Statistics {#Sec6}
----------

To determine whether there were differences in potential moderators between the intervention and control groups, we performed *t*-tests for continuous variables and *X*^2^ tests for categorical variables. The variance of the residuals was tested by a scatterplot to examine homoscedasticity and linearity. A linear regression analysis was performed for each moderator separately to identify whether the selected variable moderated the effect of the intervention on depressive symptoms at 12 months after cancer treatment. Continuous potential moderators were centered to reduce multicollinearity, and for the categorical potential moderators, educational level, employment status, and type of treatment, dummies were created. The first category was used as reference. The linear regression model contained the continuous depressive symptom score at 12 months as dependent variable. Group (intervention versus control), the centered potential moderator at baseline, the group by moderator interaction, and the centered continuous baseline depressive symptoms score were entered as independent variables. All participants who completed the baseline and the 12-month assessments were included in the full-case analyses.

In addition to the full-case, an intention to treat analyses was performed. Participants who did not complete the 12-month assessment but who minimally completed the baseline and 3-month assessments were included. To determine whether there were differences in potential moderators between the participants in the full-case analyses and the additional participants who entered the intention-to-treat analyses, *t*-tests were performed for continuous variables and *X*^2^ tests for categorical variables. Missing values were imputed in the intention-to-treat sample. Multiple imputation (10×) was carried out for missing 12 months post-cancer treatment score for depressive symptoms as well as missing baseline scores of, coping strategy, social support, cognitive functioning, and depressive symptoms. Constraints were given for each variable. All other variables were used as indicator.

The linear regression analyses were repeated and the pooled outcome of the 10 imputation datasets was used as result.

Effect sizes (ES) were calculated for each regression model in order to estimate the variance explained by the interaction term. Therefore, the proportion of variance accounted for in the model with the interaction term was subtracted from the model without the interaction term. Cohen's \[[@CR44]\] cutoff points were used to indicate a small (ES = 0.02), medium (ES = 0.15), or large (ES = 0.35) effect. In addition, the achieved power for each regression model was calculated using the statistical software of G\*Power \[[@CR45]\].

Finally, the significant moderators were post hoc probed to determine if the relation between depressive symptom and group (intervention vs control) is significant for the categories of the moderators. For the continuous moderators the categories −1 SD, mean, and +1 SD score were generated. For categorical moderators, the existing categories were used. The statistical software PROCESS of A. Hayes \[[@CR46]\] was used for the post hoc probing analyses.

All analyses were, unless otherwise stated, performed using SPSS version 21. Statistical significance was set at *p* \< 0.05 (two-tailed).

Results {#Sec7}
=======

Baseline characteristics {#Sec8}
------------------------

In total, 103 participants were randomized to the intervention group and 102 to the control group. A minimum of two assessments were available for 88 participants in the intervention group and 91 participants in the control group (intention-to-treat analyses), and 73 participants in the intervention group and 73 participants in the control group completed the 12-month post-cancer treatment assessment (full-case analyses) (Table [1](#Tab1){ref-type="table"}). The intervention and control groups were similar in terms of sociodemographic, disease-related, and treatment-related characteristics and potential moderators. In addition, there were no significant differences between the full-case participants (*n* = 146) and the additional participants who entered the intention-to-treat analyses (*n* = 33) (all *p* \> 0.05).Table 1Participant characteristics at baselineFull-case analyses, *n* = 146^a^Intention-to-treat analyses, *n* = 179^a^Intervention group (*n* = 73)Control group (*n* = 73)Intervention group (*n* = 88)Control group (*n* = 91)Age Years (mean (SD))59.5 (8)59.9 (9)60.1 (10)60.7 (10)Gender (no. (%)) Male53 (73)55 (75)62 (70)64 (70) Female20 (27)18 (25)26 (30)27 (30)Educational level (no. (%)) Low32 (44)33 (45)37 (42)37 (41) Middle26 (36)29 (40)32 (36)41 (45) High15 (21)11 (15)19 (22)13 (14)Marital status (no. (%)) Married/living together54 (74)53 (73)63 (71.6)67 (74) Single19 (26)20 (27)25 (28.4)24 (26)Employment status (no. (%)) Employed25 (34)30 (41)31 (35)34 (37) Not employed23 (32)25 (34)29 (33)34 (37) Retired16 (22)17 (23)19 (22)21 (23) Unknown9 (12)1 (1)9 (10)2 (2)Tumor site (no. (%)) Oral cavity and oropharynx46 (63)48 (66)57 (65)61 (67) Hypopharynx and larynx27 (37)25 (34)31 (35)29 (32) Unknown primary------1 (1)Tumor stage^b^ (no. (%)) I--II43 (59)47 (64)51 (58)55 (60) III--IV30 (41)26 (36)37 (42)36 (40)Type of treatment (no. (%)) Surgery17 (23)26 (36)22 (25)29 (32) Radiotherapy21 (29)21 (29)25 (28)24 (26) Chemoradiation11 (15)8 (11)12 (14)12 (13) Combination24 (33)18 (25)29 (33)26 (29)Smoking (no. (%)) Yes29 (40)33 (45)33 (38)37 (41) No44 (60)40 (55)55 (63)54 (59)Daily drinking (no. (%)) Yes26 (36)22 (30)27 (31)27 (30) No47 (64)51 (70)61 (69)64 (70)Coping strategy (mean (SD))^c,\ d^ Task oriented18 (6)18 (5)18 (6)17 (5) Emotion oriented12 (5)13 (5)12 (5)13 (5) Avoidance12 (5)12 (3)12 (5)12 (3)Social support (mean (SD))^c,\ d^2.9 (0.6)2.6 (0.5)2.9 (0.6)2.7 (0.5)Global quality of life (mean (SD))68 (23)68 (22)67 (23)66 (23)Physical functioning (mean (SD))84 (19)88 (16)84 (16)87 (18)Role functioning (mean (SD))76 (28)78 (29)76 (28)78 (29)Emotional functioning (mean (SD))64 (25)67 (25)65 (25)67 (23)Cognitive functioning (mean (SD))^d^82 (22)85 (21)84 (22)84 (22)Social functioning (mean (SD))82 (23)84 (21)83 (22)83 (21)Pain (mean (SD))35 (26)32 (25)36 (26)31 (24)Depressive symptoms (mean (SD))^d^12 (9)13 (11)13 (9)13 (10)*SD* standard deviation^a^Data is given of participants who completed a minimum of two measurements (*n* = 179)^b^Tumor stage according to the TNM Classification of Malignant Tumors^c^Incomplete baseline data for participants in full-case analyses: task-oriented coping (*n* = 129), emotion-oriented coping (*n* = 131), avoidance coping (*n* = 132), and social support (*n* = 137)^d^Incomplete baseline data for participants in intention-to-treat analyses: task-oriented coping (*n* = 154), emotion-oriented coping (*n* = 157), avoidance coping (*n* = 159), social support (*n* = 165), cognitive functioning (*n* = 178) and depressive symptoms (*n* = 178)

Moderator analyses {#Sec9}
------------------

The data was considered to be normally distributed, homoscedastic, and linear for all potential moderators. In the full-case analyses, the linear regression analyses identified four significant moderators: marital status (*b =* −6.75, *p* = 0.04), global QoL (*b =* −0.14, *p* = 0.03), emotional functioning (*b =* −0.14, *p* = 0.02), and social functioning (*b =* −0.13, *p* = 0.04) (Table [2](#Tab2){ref-type="table"}). In the intention-to-treat analyses, emotional functioning (*b =* −0.14, *p* = 0.02) and social functioning (*b =* −0.15, *p* = 0.03) were identified as moderators. A trend to significance was found for marital status (*b =* −5.96, *p* = 0.08) and global QoL (*b =* −0.14, *p* = 0.05) (Table [2](#Tab2){ref-type="table"}).Table 2Potential moderators of the intervention effect in full-case analyses and intention-to-treat analysesBL---12 MBL---12 MFull case analyses (*n* = 146)Intention-to-treat analyses (*n* = 179)Potential moderators*p*95 % CIUnstand. *β*ES^c^Power*p*95 % CIUnstand. βES^c^PowerSociodemographic, disease-related, and treatment-related variables Age0.28−0.51 to 0.15−0.180.0050.140.55−0.48 to 0.26−0.110.0050.16 Gender0.79−5.51 to 7.230.680.0000.050.69−4.94 to 7.501.280.0010.07 Education0.0040.120.0020.09  Low vs middle0.54−8.19 to 4.33−1.930.94−6.87 to 6.38−0.24  Low vs high0.38−11.65 to 4--49−3.580.83−9.85 to 7.91−0.97 Marital status0.04\*−13.02 to −0.48−6.750.0190.380.08−12.59 to 0.67−5.960.0180.43 Employment status0.0160.310.0130.31  Employed vs not employed^a^0.11−1.22 to 12.115.450.33−3.70 to 10.86−3.58  Employed vs retired^a^0.12−1.57 to 13.255.840.21−3.06 to 13.595.27 Tumor site0.27−2.58 to 9.143.280.0050.140.61−4.55 to 7.691.570.0020.09 TNM status0.68−4.65 to 7.071.210.0010.070.81−5.37 to 6.880.750.0010.07 Treatment0.0060.150.0020.09  Surgery vs radiotherapy0.26−3.14 to 11.734.30.83−6.92 to 8.680.88  Surgery vs chemoradiation0.52−6.42 to 12.553.060.96−9.95 to 10.430.24  Surgery vs combination0.51−5.07 to 10.222.581.00−7.65 to 7.660.01 Smoking0.07−0.34 to 11.065.360.0140.290.24−2.42 to 9.593.590.0070.20 Daily drinking0.58−7.75 to 4.36−1.690.0010.070.46−8.84 to 3.97−2.440.0030.11Coping strategy Task coping^b^0.97−0.52 to 0.550.010.0000.050.92−0.55 to 0.49−0.030.0010.07 Emotion coping^b^0.20−0.21 to 0.970.380.0080.170.28−0.30 to 1.010.360.0070.20 Avoidance coping^b^0.60−0.57 to 0.990.210.0010.070.76−0.67 to 0.930.130.0020.09Social support^b^0.06−10.94 to 0.24−5.350.0160.310.54−7.95 to 4.17−1.890.0040.13EORTC-QLQ-C30 and H&N35 variables Global quality of life0.03\*−0.26 to −0.02−0.140.0210.410.05−0.28 to 0.00−0.140.0240.54 Physical functioning0.55−0.21 to 0.11−0.050.0010.070.50−0.23 to 0.11−0.060.0030.11 Role functioning0.24−0.16 to 0.04−0.060.0050.140.26−0.16 to 0.05−0.060.0070.20 Emotional functioning0.02\*−0.25 to −0.02−0.140.0240.460.02\*−0.26 to −0.02−0.140.0250.56 Cognitive functioning0.18−0.22 to 0.04−0.090.0070.170.32−0.20 to 0.07−0.070.0040.13 Social functioning0.04\*−0.26 to −0.01−0.130.0180.360.03\*−0.27 to −0.02−0.150.0220.51 Pain0.31−0.06 to 0.170.060.0040.120.18−0.04 to −0.200.080.0100.27*BL* baseline measurement, *CI* confidence interval, *Unstand. β* undstandardized beta, *ES* effect size\**p* value is \<0.05^a^Patients whose employment status was unknown were not included in analyses^b^Incomplete data in full-case analyses: task-oriented coping (*n* = 129), emotion-oriented coping (*n* = 131), avoidance coping (*n* = 132), and social support (*n* = 137)^c^Cohen's (1988) cutoff points were used to indicate a small (ES = 0.02), medium (ES = 0.15), or large (ES =0.035) effect

Effect sizes ranged from 0.00 to 0.25 and achieved power from 0.05 to 0.56 for gender in the full-case analyses and emotional functioning in the intention-to-treat analyses, respectively (Table [2](#Tab2){ref-type="table"}). Post hoc probing analyses revealed a significant group difference in marital status in favor of patients who were married or living together (*b =* −4.25, *p* = 0.01) compared to patients who were single. Furthermore, patients with low (−1 SD) baseline scores on global QoL (*b =* −5.65, *p* = 0.01), emotional functioning (*b =* −5.99, *p* = 0.00), and social functioning (*b =* −5.41, *p* = 0.01) differed significantly from patients with mean or high (+1 SD) baseline scores (Table [3](#Tab3){ref-type="table"}). This indicates that patients who were married or living together, and patients with low baseline scores on global QoL, emotional functioning, and social functioning responded better to the NUCAI than patients who were single or had mean or high baseline scores. Regression lines for each relationship between group (control vs NUCAI) and depressive symptom score at 12 months post-cancer treatment as moderated by marital status, global QoL, emotional functioning, or social functioning are given in Fig. [1](#Fig1){ref-type="fig"}.Table 3Post hoc probing of the significant moderatorsModerator baseline value*p* value95 % CI*β* valueMarital statusMarried/living together--0.01\*−7.49 to −1.01−4.25Single--0.36−2.86 to 7.862.50Global quality of life−1 SD45.520.01\*−9.61 to −1.70−5.65Mean68.260.08−5.25 to 0.31−2.47+1 SD91.010.72−3.23 to 4.650.71Emotional functioning−1 SD40.300.00\*−9.96 to −2.01−5.99Mean65.260.07−5.38 to 0.20−2.59+1 SD90.220.69−3.12 to 4.730.80Social functioning−1 SD60.700.01\*−9.39 to −1.44−5.41Mean83.110.08−5.26 to 0.32−2.47+1 SD1000.89−3.75 to 3.25−0.25Analyses were performed in the full-case group (*n* = 146)*CI* confidence interval, *β* beta, *SD* standard deviation\**p* value is \<0.05Fig. 1Regression lines for the relationship between group (intervention vs control) and depressive symptom score at 12 months post-cancer treatment, as moderated by marital status (**a**), global quality of life (**b**), emotional functioning (**c**), or social functioning (**d**)

Age, gender, educational level, employment status, tumor stage, type of treatment, smoking, daily drinking, task coping, emotion coping, avoidance coping, social support, physical functioning, pain, tumor site, role functioning, and cognitive functioning did not moderate the effect of the NUCAI on depressive symptoms 12 months posttreatment.

Discussion {#Sec10}
==========

The present study investigated moderators of the response to a nurse-led psychosocial intervention, the nurse counseling and after intervention (NUCAI). The NUCAI has been found to decrease depressive symptoms 1 year after treatment of head and neck cancer \[[@CR11]\]. In this secondary analysis, we found that patients who were married/living together had low baseline scores on global QoL, emotional functioning, or social functioning benefitted more of the NUCAI, resulting in lower depressive symptom scores 12 months posttreatment, than patients who were single or had mean or high baseline scores on global QoL, emotional functioning or social functioning.

Patients with low baseline scores for emotional functioning showed a statistical significant improvement of almost 6 points on the depressive symptoms scale. Although a minimal clinically important difference of the CES-D is not yet established, we considered this difference as clinical significant, according to Norman et al. who showed that a change of half a standard deviation indicates a clinical relevant difference \[[@CR47]\]. Only one study was found in the literature that explored the moderating effect of emotions in patients with cancer. Manne et al. \[[@CR28]\] showed, in a large RCT involving women with gynecological cancer, that women who were more expressive of positive emotions benefitted more from a supportive counseling intervention than women who were less expressive of positive emotions. Results for negative emotions were not computed because of the low internal consistency of the data. Our results are inconsistent with those of Manne et al. \[[@CR28]\], which could be due to the different types of cancer studied and the gender of the participants (solely women versus 70 % men in our study). In addition, Gamper et al. \[[@CR49]\] recently defined emotional functioning as a variable that covers aspects of anxiety, depression, and general distress, which is much broader than expression of emotions alone.

We also found that patients with head and neck cancer who had low scores for social functioning at baseline responded statistically and clinically significantly better, with a decrease of 5.4 points on the depressive symptoms scale, to the NUCAI than patients with high scores for social functioning. Balderson et al. \[[@CR27]\] reported that social/family well-being was related to lower psychological distress in patients with prostate cancer, which is in line with our results.

The full-case analyses showed that patients who were married/living together had fewer depressive symptoms (a decrease of 4.3 points) 1 year after cancer treatment than patients who were single and thus benefited more from the NUCAI. The intention-to-treat analyses showed the same trend. It should be mentioned that, with the NUCAI, patients are encouraged to bring their partners to intervention sessions. Mikoshiba et al. \[[@CR19]\] found that living alone was associated with an increased likelihood of depressive symptoms in patients with liver cancer. Perhaps if a partner follows the intervention with the patient, he/she can discuss the intervention with the patient at home and might stimulate and support the patient.

A poorer global QoL at baseline was also found to be a moderator of the effect of the NUCAI in both the full-case and intention-to-treat analyses, with patients with a worse global QoL at baseline responding better (a decrease of 6.7 points on the depressive symptoms scale) to treatment than patients with a better global QoL. While we did not find any articles in the literature that expressly investigated this, several studies have shown that higher depressive symptom scores or depression are related to a lower global QoL in cancer patients \[[@CR19], [@CR25], [@CR26]\]. Overall, no significant improvements were found for patients who had high (+1 SD) global QoL, emotional functioning, and social functioning scores. The CES-D is found to be sensitive to changes in depressive symptoms after intervention \[[@CR48]\]; however, it could be that these patients with high scores had little room to improve and therefore only minor changes in depressive symptoms could be established. This should be considered when offering the NUCAI to patients.

Other studies have shown that social demographic variables (age, gender, educational level, working status), disease-related variables (tumor stage, type of treatment), or health behavior-related variables (smoking, drinking) are related to increased levels of depressive symptoms \[[@CR13], [@CR14], [@CR16]--[@CR19]\]. We did not find these variables to moderate the response to the NUCAI. The NUCAI is patient driven, and it is possible that the nurses personalized the intervention on the basis of these variables, thereby providing a tailored intervention. Overall, there is no evidence at this point that clinical variables should be used when selecting patients with head and neck cancer for a psychosocial intervention. Hence, the NUCAI seems to be of most benefit for head and neck cancer patients who have poor scores on emotional functioning, social functioning, and global QoL. In addition, patients who are single should be given extra attention and should be encouraged to bring a relative or friend to the intervention sessions.

Interestingly, the European Organisation for Research and Treatment of Cancer (EORTC) is developing a computerized adaptive testing measure based on an item bank for, among others, emotional functioning, to be used as a screening tool in cancer patients \[[@CR49]\]. This extensive project is in its last phase and seems to be promising for future screening possibilities and could be extended with the other moderators found in this study.

Our findings represent a first step to distinguishing between patients with head and neck cancer who might or might not benefit from a psychosocial intervention. However, the results are secondary analyses and the following limitations should be considered when interpreting outcome. First, this study was not powered for moderator analyses but for the efficacy of the intervention. The effect sizes of the significant moderators varied between 0.018 and 0.024 which is considered to be a small effect \[[@CR44]\]. In addition, the power varied between 0.36 and 0.46 which implicate that a larger sample size is needed to detect a relationship between the moderator and the intervention effect without committing a type II error. In addition, because of the explorative nature of the study, the *p* values were not adjusted for multiple testing. Lastly, not all the variables that are associated with depressive symptoms could be incorporated in the analyses because they were not measured in the NUCAI study.

In conclusion, little is known about the variables that moderate the response to a psychosocial intervention in head and neck cancer patients. Analyses showed that patients who had poor scores for emotional functioning, social functioning, and global QoL at baseline and who were married or living together benefitted more from the NUCAI than patients with high scores and who were single. We suggest that the screening of patients with head and neck cancer for eligibility for a psychosocial intervention should be based on patients' global QoL, emotional functioning, and social functioning, with extra attention being paid to patients who are single. Because of the explorative nature of this study further, well powered, research is necessary to replicate our results and to provide personalized patient care, so that available resources (time, staff, and money) can be used in the best possible way.
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